Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Accounts Payables: 2011-2025

Historic Accounts Payables for Abeona Therapeutics (ABEO) over the last 15 years, with Sep 2025 value amounting to $5.9 million.

  • Abeona Therapeutics' Accounts Payables rose 112.51% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 112.51%. This contributed to the annual value of $3.4 million for FY2024, which is 85.20% up from last year.
  • Per Abeona Therapeutics' latest filing, its Accounts Payables stood at $5.9 million for Q3 2025, which was down 19.22% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Accounts Payables ranged from a high of $7.3 million in Q2 2025 and a low of $1.5 million during Q2 2021.
  • Moreover, its 3-year median value for Accounts Payables was $3.4 million (2024), whereas its average is $3.8 million.
  • As far as peak fluctuations go, Abeona Therapeutics' Accounts Payables plummeted by 58.13% in 2022, and later soared by 136.75% in 2025.
  • Abeona Therapeutics' Accounts Payables (Quarterly) stood at $4.3 million in 2021, then slumped by 58.13% to $1.8 million in 2022, then climbed by 2.60% to $1.9 million in 2023, then soared by 85.20% to $3.4 million in 2024, then soared by 112.51% to $5.9 million in 2025.
  • Its Accounts Payables was $5.9 million in Q3 2025, compared to $7.3 million in Q2 2025 and $5.0 million in Q1 2025.